API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/biolinerx-announces-poster-presentation-on-economic-model-data-for-aphexda-motixafortide-as-part-of-cd34-hematopoietic-stem-cell-mobilization-in-patients-with-multiple-myeloma-at-ispor-2024-302135166.html
https://www.prnewswire.com/news-releases/biolinerx-announces-poster-presentation-on-apheresis-center-efficiency-and-cxcr4-antagonists-including-aphexda-motixafortide-in-patients-with-multiple-myeloma-at-the-asfa-2024-annual-meeting-302118663.html
https://www.prnewswire.com/news-releases/biolinerx-strengthens-intellectual-property-estate-with-notice-of-allowance-for-us-patent-covering-method-of-manufacturing-motixafortide-bl-8040-suitable-for-large-scale-production-302078254.html
https://www.prnewswire.com/news-releases/biolinerx-announces-first-patient-dosed-in-randomized-phase-2-combination-clinical-trial-evaluating-motixafortide-in-first-line-pancreatic-cancer-pdac-302073363.html
https://www.prnewswire.com/news-releases/biolinerx-announces-acceptance-of-two-poster-presentations-on-aphexda-motixafortide-for-cd34-hematopoietic-stem-cell-hsc-mobilization-in-patients-with-multiple-myeloma-at-the-2024-tandem-meetings-of-astct-and-cibmtr-302063517.html
https://www.prnewswire.com/news-releases/biolinerx-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-motixafortide-for-cd34-hematopoietic-stem-cell-mobilization-for-gene-therapies-in-sickle-cell-disease-302020452.html
https://www.prnewswire.com/news-releases/biolinerx-entered-exclusive-license-agreement-to-motixafortide-in-asia-advisored-by-msq-ventures-301972192.html
https://www.prnewswire.com/news-releases/biolinerx-announces-encouraging-data-from-pilot-phase-of-phase-2-combination-clinical-trial-with-motixafortide-in-first-line-pancreatic-cancer-pdac-301941126.html
https://www.prnewswire.com/news-releases/biolinerx-announces-acceptance-of-oral-presentation-on-pilot-phase-data-from-phase-2-combination-clinical-trial-with-motixafortide-in-first-line-pdac-at-aacr-special-conference-on-pancreatic-cancer-301931109.html
https://www.prnewswire.com/news-releases/biolinerx-announces-fda-approval-of-aphexda-motixafortide-in-combination-with-filgrastim-g-csf-to-mobilize-hematopoietic-stem-cells-for-collection-and-subsequent-autologous-transplantation-in-patients-with-multiple-myeloma-301923206.html
https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-randomized-phase-2-clinical-trial-in-first-line-metastatic-pancreatic-cancer-based-on-preliminary-data-from-single-arm-pilot-phase-combination-trial-includes-investigational-candidate-motixaforti-301878087.html
https://www.prnewswire.com/news-releases/biolinerx-announces-publication-in-nature-medicine-of-its-genesis-phase-3-clinical-trial-data-evaluating-motixafortide-and-g-csf-in-stem-cell-mobilization-for-autologous-transplantation-in-multiple-myeloma-301798798.html
https://www.prnewswire.com/news-releases/biolinerx-announces-clinical-trial-collaboration-with-washington-university-school-of-medicine-to-evaluate-motixafortide-for-cd34-hematopoietic-stem-cell-mobilization-for-gene-therapies-in-sickle-cell-disease-301762544.html
https://www.prnewswire.com/news-releases/biolinerx-announces-us-fda-acceptance-of-new-drug-application-for-aphexda-motixafortide-in-stem-cell-mobilization-301674304.html
https://www.prnewswire.com/news-releases/biolinerx-announces-presentations-on-cost-effectiveness-of-motixafortide-in-multiple-myeloma-and-program-for-potential-motixafortide-indication-expansion-in-gene-therapy-at-the-64th-american-society-of-hematology-ash-annual-meet-301667660.html
https://www.prnewswire.com/news-releases/biolinerx-announces-us-commercialization-plan-for-aphexda-motixafortide-in-stem-cell-mobilization-301633337.html
https://www.prnewswire.com/news-releases/biolinerx-announces-submission-of-new-drug-application-nda-to-fda-for-motixafortide-in-stem-cell-mobilization-301621832.html
https://www.prnewswire.com/news-releases/biolinerx-announces-collaboration-agreement-with-genfleet-therapeutics-to-further-develop-motixafortide-in-pancreatic-ductal-adenocarcinoma-pdac-301576754.html
https://www.prnewswire.com/news-releases/biolinerx-announces-successful-completion-of-pre-nda-meeting-with-fda-for-motixafortide-for-stem-cell-mobilization-in-multiple-myeloma-patients-301462623.html
https://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2021-financial-results-and-provides-corporate-update-301427840.html
https://seekingalpha.com/news/3752377-biolinerx-shares-rise-8-after-motixafortide-multiple-myeloma-pharmacoeconomic-study-results
https://www.prnewswire.com/news-releases/biolinerx-announces-final-results-from-phase-2a-combatkeynote-202-triple-combination-study-of-motixafortide-in-second-line-metastatic-pancreatic-cancer-pdac-301193912.html
https://www.prnewswire.com/news-releases/biolinerx-announces-final-results-from-phase-2a-combatkeynote-202-triple-combination-study-of-motixafortide-in-second-line-metastatic-pancreatic-cancer-pdac-301193912.html
https://www.prnewswire.com/news-releases/biolinerx-announces-positive-results-from-interim-analysis-of-genesis-phase-3-trial-of-motixafortide-bl-8040-in-stem-cell-mobilization-301163726.html
https://www.biospace.com/article/releases/biolinerx-announces-positive-results-from-interim-analysis-of-genesis-phase-3-trial-of-motixafortide-bl-8040-in-stem-cell-mobilization/#:~:text=)%20News%20(659)-,BioLineRx%20Announces%20Positive%20Results%20from%20Interim%20Analysis%20of%20GENESIS%20Phase,8040)%20in%20Stem%20Cell%20Mobilization&text=%22Stem%20cell%20mobilization%20represents%20a,of%20patients%20are%20poor%20mobilizers.
https://www.prnewswire.com/news-releases/biolinerx-announces-notice-of-allowance-from-uspto-for-patent-covering-motixafortide-bl-8040-in-combination-with-anti-pd-1-for-the-treatment-of-any-type-of-cancer-301012614.html